Myocardial Infraction
|
Patients who have suffered a
myocardial infarction – a heart attack – had lower risk
of re-infarction when they were given Wobenzym®.
Normalization of lymphocytes, and a
lowering of
circulating immune complexes was observed. A parallel study of myocardial infarction patients and two groups of rabbits reported a “significant decrease of cholesterol level” in both the clinical and the experimental studies. They concluded that “it can be recommended to use Wobenzym in complex treatment of myocardial infarction patients to reduce risk factors of reinfarction.” From FREQUENTLY ASKED QUESTIONS, with answers by Joseph J Collins, RN, ND Read the special section: CARVIOVASCULAR AND LYMPHATIC SYSTEMS & WOBENZYM® |
What the literature says about Systemic Enzyme Support and:
Systemic
enzyme therapy in the treatment of patients with myocardial
infarction.
Sledzevskaja U. K., Šumakov V. A., Bratus V. B.,
Babij A., Malinovskaja U. Z., Gavrilenko T. U., Terzov A. U.
Systemic enzyme therapy in the treatment of patients with myocardial
infarction. Žurnal praktièeskogo vraèa 1997, No. 3, pp. 43 – 44. 11
KR [Czech translation of abstract]
An immune statute of myocardial infarction (MI)
patients is significantly impaired. Preparation Wobenzym (Mucos
Pharma, Germany) shows a hypolipidemic and immunonormalizing effect,
although its applicationh in the treatment of MI patients has not
been studied yet.
Two groups of patients with hyperlipidemia was
administered with Wobenzym : A (30 patients - 9 coated tablets for
10 days) B (13 patients - 9 coated tablets for 30 days). Patients
received also beta blockers, nitrates and aspirin.
Controlled parameters were: level of cholesterol,
triglycerides, HDL, LDL and VLDL, coefficient of atherogenity,
lipoprotein level, activity – concentration of diene conjugates,
malonic acid dialdehyd, catalase activity. Parameters of cell and
humoral imunity –count of monocytes, neutrophil granulocytes,
phagocytary activity, level of imunoglobulins, circulation immune
complexes, antibodies against infarcted myocardium, monoclonal
antibodies – were followed, too.
In parallel with this clinical study an animal
experiment was conducted on two groups of rabbits with alimentary
hypercholesterolemia. First group of animals was control, second
group received Wobenzym in the daily dose 3 times higher than the
calculated dose per 1 kg of patients` body weight. Following
parameters were controlled during 2, 4, 6 and 8 weeks : level of
cholesterol in plasma, catalase activity, malonic acid dialdehyd,
coefficient of atherogenity, monocyte count.
Lowering of cholesterol level by 12% and
lipoproteins by 16% was observed in the patients from first group
already after 10 days, whereas patients from the second group showed
decrease of cholesterol level by 24% and lipoproteins by 31% within
one month. Level of malonic acid dialdehyde showed no changes for 10
days, after one month was lowered.
These results support an antiatherogenic effect of
Wobenzym which can be seen after 10 days and antioxidant effect
which can be seen after long-term treatment.
In 2/3 of MI patients a lowered level of B and T
lymphocytes and T helpers and in 1/2 of patients lowering of T
suppressors and natural killers were found.Within one month the
activity of cellular imunity increased (normalization of T helper
and natural killer level). An elevated level of circulating imune
complexes was found in 80% of patients from both groups. Wobenzym
therapy led to the decrease of immune complex level by 38% in 88% of
patients in second group. Additionally, in all patients a higher
titer of antibodies against infarcted myocardium was observed.
Antibody titer decreased from 16 to 9 units in 50 % of patients in
the second group after Wobenzym therapy.
Antiatherogenic and hypolipidemic effect of
Wobenzym was experimentally verified. Treated animals showed
cholesterol level nearly two times lower than animals in control
group. In treated animals a decreased activity of oxidative
reactions and increased activity of antioxidative enzymes (seen in
the level of malonic acid dialdehyde) was observed. In the group of
treated animals an increased catalase activity was measured.
Obtained results support a therapeutical effect of
Wobenzym in the complex pathogenetic treatment of patients with
myocardial infarction.
Immunonormalizing, antiatherogenic and
antioxidative effects of Wobenzym influence the risk of
reinfarction.
Investigation of the effect of long-term Wobenzym
treatment on MI patients is planed.
Poster Reference Number 28.
Systemic
enzyme treatment as a method of secondary prevention in patients
after myocardial infarction in the rehabilitation period.
Sledzevskaya I.K., Loboda M.V., Kolesnik E.A.,
Babiy L.N., Fisenko L.I. Systemic enzyme treatment as a method of
secondary prevention in patients after myocardial infarction in the
rehabilitation period. II Mediterranean Congress of Physical
Medicine and Rehabilitation, 20-23 May, 1998, Valencia, Spain.
Abstracts- pp. 137. 489 KA (19-08-3) Ukrainian Institute of
Cardiology,"Ukrprofzdravniza", Kiyev, Ukraine
Abstract: Despite its proved hypolipidemic and
immunocorrective effects, Wobenzym ("Mucos Pharma" Germany) has not
been used in patients with myocardial infarction (MI) in period of
rehabilitations.
The aim of this study was the estimation of
influence treatment with Wobenzym on lipids parameters, antioxidant
activity and immunological indices in patients after myocardial
infarction.
30 myocardial infarction patients in 3rd-4th week
of the disease were treated with Wobenzym. The patients also
received beta-adrenoblockers, nitrates, aspirin and inhibitors ACE.
Parallel experimental studies with two rabbit
groups with a hypercholesterolemia model were carried out.
Cholesterol content in plasma, blood pro- and antioxidant parameters
and state of blood monocytes were estimated.
Evident hypolipidemic effects (significant
decrease of cholesterol level) and immunocorrecting effects
(significant decrease of titer of antibodies to the infarcted
myocardium and circulating immune complexes) of Wobenzym were
demonstrated in clinical and experimental study.
Based on obtained results it can be recommended to
use Wobenzym in complex treatment of myocardial infarction patients
to reduce risk factors of reinfarction.
Poster Reference Number 27.
New
approaches to modern cardiology based on systemic enzyme therapy.
Kovalenko V.N., Sledzevskaya I.K., Ryabokon E.N., Gavrilenko T.I., Terzov A.I. N.D. New approaches to modern cardiology based on systemic enzyme therapy. Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 101-111 - ISSN 0255-9625 218 K/375 (17-10-3)- (19-05-3) Strazhesko Institute of Cardiology, Academy of Medical Sciences, Ukraine.
Summary: Enzyme therapy is a modern medical method
based on the complex action of targeted mixtures of hydrolytic
enzymes on the main pathological processes by nonspecific and
specific immune mechanisms. The efficiency of enzyme therapy is
supported by studies performed by a group of Ukrainian doctors on
the treatment of postmyocardial infarction patients that led to
normalization of cholesterol levels. In these studies, the treatment
consisted of Wobenzym®.
Under the influence of this drug, some of the
immune parameters in patients with postmyocardial infarction
returned to normal. Nevertheless, many factors of immune
inflammation in postmyocardial infarction patients have not yet been
researched and the principles of assignment of enzyme therapy during
rehabilitation have not been developed. Immune inflammation in
postmyocardial infarction patients was investigated and the research
concentrated on the influence of enzymes on immune factors during
rehabilitation.
Seventy-three patients with postmyocardial
infarction were divided into two groups: group 1 consisted of 52
patients treated with Wobenzym® for 6 months and group 2 consisted
of 21 patients given basic therapy (aspirin, b-blockers and
nitrates) only. Material for research was venous blood, which was
taken in the morning prior to the beginning of Wobenzym® therapy and
again after 1, 3 and 6 months of treatment. Biochemical research
included tracing of cholesterol, triglycerides and atherogenic
potential.
Immunology research included study of the factors
of immunity, cytokine levels and immunoinflammatory reaction.
Postmyocardial infarction patients showed changes in lipid,
immunological and circulatory dynamics. This study concentrated on
analyzing the influence of enzyme therapy on changes in lipid,
immunological and circulatory dynamics and determination of the
efficiency of its extended application. A set of major parameters
that are important in myocardial infarction are described.
It was found that inclusion of Wobenzym® in the
complex treatment of postmyocardial infarction patients is
beneficial, as this drug has immuno- and lipid correction effects.
Systemic enzyme therapy helps to improve the patient's biochemical
and immune abnormalities.
Poster Reference Number 29.